Sofinnova Crossover I SLP 13D/13G Filings for MaxCyte, Inc. (MXCT)

Sofinnova Crossover I SLP 13D and 13G filings for MaxCyte, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2023-02-13
2:08 pm
Sale		 2022-12-31 13G MaxCyte, Inc.
MXCT		 Sofinnova Crossover I SLP 4,610,693
4.500%		 -500,000decrease
(-9.78%)		 Filing
2022-02-11
10:59 am
Purchase		 2021-12-31 13G MaxCyte, Inc.
MXCT		 Sofinnova Crossover I SLP 5,110,693
5.100%		 5,110,693increase
(New Position)		 Filing